Screening Donors, Fecal Microbiota Transplant Program in Ulcerative Colitis

Not Applicable

Recruiting

• Conditions: Ulcerative Colitis Flare
• Interventions: Other: Fecal Microbiota transplant (FMT)

• Registration Number: NCT04926103
• Lead Sponsor: Hamilton Health Sciences Corporation

Brief Summary

The investigators intend to screen for new donors, given that there may a donor effect (PubMed ID: 25857665), with some donors not inducing remission in any patient whilst others inducing remission in 20-40% of cases. It is important to give UC patients participating in RCTs stool that has been demonstrated to be effective in some patients. We therefore propose to conduct an open label study in patients with active UC to ensure new donors are effective at inducing remission in some patients. Patients that have FMT will relapse within 18 months (PubMed ID: 25857665) although further FMT therapy induces remission so it is possible that maintenance FMT will result in long term remission, but this needs evaluation. We will therefore follow UC patients that have responded to FMT long term in this open label study.

Detailed Description

This is an open label study with all UC patients receiving FMT. Up to 200 patients with active UC will be recruited to the study.

Study Timeline

• Study First Submitted: 2021-05-12
• Study First Submitted QC: 2021-06-10
• Study First Posted: 2021-06-14
• Study Start: 2022-07-01
• Status Verified: 2024-09
• Last Update Submitted: 2024-09-30
• Last Update Posted: 2024-10-01
• Primary Completion: 2028-10-01
• Study Completion: 2029-05-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Patients aged 18 or over
2. Active UC defined as a Mayo score (7) >3
3. A Mayo endoscopic score (7) >0
4. Females of child-bearing potential must be willing and able to use acceptable contraception as per Appendix III. II. b. Toxicity section of the Health Canada Guidance

Read More

Exclusion Criteria

1. Participating in another intervention study for UC
2. Unable to give informed consent
3. Severe comorbid medical illness
4. Severe UC requiring hospitalization.
5. Increase in medical therapy for UC in the last 12 weeks. Continued treatment with 5-ASA, azathioprine, 6-mercaptopurine or anti-TNF therapy (e.g. infliximab) will be permitted if taken at stable dose for ≥12 weeks prior to randomization. Relapse on a stable dose (same dose for at least 2 weeks) or a tapering dose of steroids will also be permitted provided the dose of steroid is not increased again. Stable intake of probiotic therapy also permitted.
6. Antibiotic therapy in the last 30 days.
7. Pregnant women.
8. Patients with clinically significant hepatic dysfunction at the time of screening: ALT > 5 times the upper normal range.
9. Patients with clinically significant renal dysfunction at the time of screening: serum creatinine > 300 µmol/L
10. Any condition, in the opinion of the investigator, that the treatment may pose a health risk to the subject.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Open label FMT therapy	Fecal Microbiota transplant (FMT)	FMT from a related or unrelated healthy donor screened for known communicable disease

Primary Outcome Measures

Name	Time	Method
Efficacy of FMT donors at inducing UC remission	9 weeks	Suitability of FMT donors at inducing remission in active UC (remission defined as a Mayo score (7) \< 3 with an endoscopic Mayo score = 0 at the end of 8 weeks of FMT).
Efficacy of FMT at maintaining remission in UC	3 years	Maintenance of remission of UC after three years in those who achieve initial remission with FMT. This is defined as no relapse over three years that requires any medical therapy other than more intense FMT therapy

Secondary Outcome Measures

Name	Time	Method
Efficacy of FMT at relieving PRO2 symptoms	9 weeks	A score of zero on the first two questions of the Mayo Score
Stool microbiota predicting FMT success	9 weeks	Comparison of stool microbiota evaluated by 16s RNA and metagenomics in those achieving remission with FMT versus those that are not successful
Efficacy of FMT at in inducing histological remission in active UC	9 weeks	Histological remission with no active inflammation on rectal and sigmoid biopsies
Adverse effects of FMT	3 years	Adverse effects associated with FMT therapy
Efficacy of FMT at improving Quality of life	9 weeks and 3 years	Improvement in quality of life from baseline measured by EQ5D
Mucosal microbiota predicting FMT success	9 weeks	Comparison of mucosal microbiota evaluated by 16s RNA and metagenomics in those achieving remission with FMT versus those that are not successful

Trial Locations

Locations (1)

Hamilton Health Sciences / McMaster University; 🇨🇦 Hamilton, Ontario, Canada